Biomark Diagnostics Inc. (CSE:BUX)

Market Cap	54.27M
Revenue (ttm)	123.42K
Net Income (ttm)	-1.65M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,500
Average Volume	17,563
Open	0.4500
Previous Close	0.4800
Day's Range	0.4500 - 0.4500
52-Week Range	0.2000 - 0.5000
Beta	-0.07
RSI	56.53
Earnings Date	Feb 26, 2026

About Biomark Diagnostics

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BUX

Financial Performance

In 2024, Biomark Diagnostics's revenue was 154,216, a decrease of -5.52% compared to the previous year's 163,220. Losses were -1.93 million, 35.0% more than in 2023.